9 Meters Biopharma Inc   (NMTR)
Other Ticker:  
Price: $0.0722 $-0.05 -42.970%
Day's High: $0.1127 Week Perf: -57.68 %
Day's Low: $ 0.07 30 Day Perf: -89.24 %
Volume (M): 9,958 52 Wk High: $ 1.79
Volume (M$): $ 719 52 Wk Avg: $0.93
Open: $0.11 52 Wk Low: $0.07

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 14
 Employees 27
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 0

9 Meters Biopharma Inc
9 Meters Biopharma Inc is a clinical-stage biotechnology company that focuses on developing innovative therapies for patients with rare and orphan diseases. The company was founded in 2015 and is headquartered in Raleigh, North Carolina.

The primary goal of 9 Meters Biopharma Inc is to provide new and effective treatments for patients with rare diseases, many of whom have limited treatment options. The company is committed to developing therapies that can address the underlying cause of these diseases, rather than just treating symptoms.

One of the key areas of focus for 9 Meters Biopharma Inc is celiac disease, a condition in which the immune system attacks the small intestine when gluten is ingested. The company is developing a drug called Larazotide Acetate, which is a peptide that helps to prevent the immune system from attacking the small intestine. The drug is currently in Phase 3 clinical trials and has the potential to become the first FDA-approved treatment for celiac disease.

9 Meters Biopharma Inc is also developing a drug called NM-002, which is designed to treat a rare genetic disorder called NASH (non-alcoholic steatohepatitis). NASH is a condition in which fat builds up in the liver and can cause inflammation, scarring, and liver damage. NM-002 is currently in preclinical development and has shown promise in animal studies.

In addition to its work in celiac disease and NASH, 9 Meters Biopharma Inc is exploring potential treatments for other rare and orphan diseases. The company has a pipeline of drug candidates, including several that are in preclinical development.

Overall, 9 Meters Biopharma Inc is a promising biotech company that is dedicated to developing innovative therapies for patients with rare and orphan diseases. Its focus on addressing the underlying causes of these conditions sets it apart from other companies in the industry, and its commitment to patient care and advocacy is evident in its mission and values. With several promising drug candidates in its portfolio, 9 Meters Biopharma Inc has the potential to make a significant impact on the lives of patients with rare diseases.

   Company Address: 4509 Creedmoor Road Raleigh 27612 NC
   Company Phone Number: 275-1933   Stock Exchange / Ticker: NASDAQ NMTR
   NMTR is expected to report next financial results on March 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

9 Meters Biopharma Inc

9 Meters Biopharma Inc Faces Operating Shortfall of $12.8 Million in Q1 2023, CFO Unveils Plan for Steady Growth

As the Major Pharmaceutical Preparations industry continues to dominate the news with drug discoveries and new vaccines, some of the lesser-known players are also sharing their earnings statements. 9 Meters Biopharma Inc, a relatively new player in the industry, recently announced its earnings for the first quarter of 2023, revealing an operating shortfall of $-12.787491 million.
Despite the negative numbers, the company's CFO is working on financial plans to secure steady business and meet its goals. Although the net loss extended from $-11.352 million during the same period in 2022, the company is still expected to report more financial earnings on August 14, 2023.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com